Top Story
DEA Schedule III Cannabis Rescheduling August 2026 Morning Update Federal Administrative Review Nears Final Phase as Industry Prepares for Transformative Tax and Banking Implications
TL;DR: The DEA’s formal rulemaking process for cannabis rescheduling from Schedule I to Schedule III reached a critical phase in August 2026, with the administrative
Top Movers
Latest Analysis
AYR Wellness AYRWF Friday August 21 2026 Midday Analysis Florida Multi-State Retail Depth and Balance Sheet Optimization Define Second-Half 2026 Free Cash Flow Recovery Path
TL;DR: AYR Wellness (AYRWF) enters Friday’s midday session as one of the more closely watched mid-cap MSOs in the cannabis equity space, with investors focused
TerrAscend Corp TRSSF Friday August 21 2026 Midday Analysis Pennsylvania New Jersey Market Leadership and Improving Operational Leverage Set Stage for Q3 2026 Earnings Catalyst
TL;DR: TerrAscend Corp (TRSSF) enters Friday’s midday session with a strengthening operational thesis anchored by dominant retail positions in Pennsylvania and New Jersey, two of
Curaleaf Holdings CURLF Thursday August 20 2026 Evening Analysis Operational Consolidation and Q3 Earnings Catalyst Position Largest US MSO for Second-Half 2026 Recovery
TL;DR: Curaleaf Holdings (CURLF) enters Thursday’s close as the largest US multi-state operator continues its operational consolidation cycle, with investors focused on Q3 2026 earnings
Cannabis Equities Thursday August 20 2026 Morning Overview Schedule III Momentum and Q3 Earnings Season Catalysts Define Pre-Market Positioning for Cannabis Sector
TL;DR: Cannabis equities enter Thursday’s session positioned within the broader Q3 2026 earnings season catalyst window, with Schedule III administrative review progress and sequential profitability
Canopy Growth CGC Thursday August 20 2026 Morning Analysis Canadian LP Restructuring and Brand Portfolio Optimization Position Profitability Recovery Ahead of Q3 Earnings
TL;DR: Canopy Growth Corporation (NYSE: CGC) enters Thursday’s session carrying momentum from ongoing restructuring initiatives under CEO David Klein, as the Canadian multi-national LP continues
DEA Schedule III Cannabis Rescheduling August 2026 Morning Update Federal Administrative Review Nears Final Phase as Industry Prepares for Transformative Tax and Banking Implications
TL;DR: The DEA’s formal rulemaking process for cannabis rescheduling from Schedule I to Schedule III reached a critical phase in August 2026, with the administrative